Treatment of Viral Pneumonia

Supportive Care

Patients should rest in bed with continuous monitoring of vital signs (heart rate, pulse oxygen saturation, respiratory rate, blood pressure) 1
Regular laboratory monitoring is essential, including blood routine, CRP, PCT, organ function tests, coagulation function, arterial blood gas analysis, and chest imaging 1
Nutritional support is critical:
- For patients with nutrition risk scores <3 points: provide protein-rich foods with ideal energy intake of 25-30 kcal/(kg·d) and protein intake of 1.5 g/(kg·d) 2
- For patients with nutrition risk scores ≥3 points: provide early nutritional support with increased protein intake through oral supplements 2-3 times daily (≥18g protein/time) 2
- Consider enteral nutrition tube placement when oral intake is insufficient 3
Symptomatic fever management: When temperature exceeds 38.5°C, ibuprofen can be used (oral, 0.2g per time, every 4-6h as needed, maximum 4 times in 24h) 4

Provide effective oxygen therapy based on severity, with options including:
- Nasal catheter 2
- Mask oxygen 2
- High flow nasal oxygen therapy (HFNO) 2
- Non-invasive ventilation (NIV) 5
- Invasive mechanical ventilation 5
For patients with refractory hypoxemia not responding to conventional measures, consider Extracorporeal Membrane Oxygenation (ECMO) 1, 2
For patients with moderate-severe ARDS (PaO₂/FiO₂ < 150), implement protective lung ventilation strategies with higher PEEP, prone positioning for >12 hours daily, and consider deep sedation and analgesia muscle relaxation within the first 48 hours of mechanical ventilation 5

Currently, there is limited evidence from randomized controlled trials supporting specific antiviral treatments for most viral pneumonias 1
When used, antiviral therapy should be initiated as early as possible in the disease course 1

Avoid blind or inappropriate use of antibacterial drugs, especially broad-spectrum combinations 1
Perform bacteriological surveillance and administer appropriate antibacterial drugs only when secondary bacterial infection is suspected 1
For mild cases with suspected bacterial co-infection, consider antibiotics effective against community-acquired pneumonia (amoxicillin, azithromycin, or fluoroquinolones) 1
For severe cases, empirical antibacterial treatment should cover all possible pathogens, with de-escalation once the causative bacteria are identified 1

For patients with dyspnea, cough, and increased respiratory secretions, consider selective (M1, M3) receptor anticholinergic drugs to reduce secretions and improve pulmonary ventilation 3, 2
Use H2 receptor antagonists or proton pump inhibitors in patients with gastrointestinal bleeding risk factors 3, 2
Evaluate risk of venous thromboembolism and use prophylactic low-molecular-weight heparin or heparin in high-risk patients without contraindications 3, 2

For patients with rapid disease progression or severe illness, methylprednisolone 40-80 mg per day (not exceeding 2 mg/kg daily) may be considered for short periods (3-5 days) 1, 2
Corticosteroids may improve clinical symptoms, reduce disease progression, and accelerate absorption of lung lesions in severe cases, but do not shorten hospital stay 1
Be cautious of potential adverse reactions with hormone therapy 1

Initiate beta‑lactam antibiotics immediately to cover the anaerobic pathogen in patients with confirmed co‑infection 6.
First‑line regimen: amoxicillin‑clavulanate, which provides activity against typical and anaerobic organisms including Fusobacterium 6.
Alternative regimen: a third‑generation cephalosporin may be used when a beta‑lactam allergy is present 6.
Macrolides and quinolones should be avoided because of their potential to prolong the QT interval, especially when combined with other QT‑prolonging agents used for COVID‑19 7.
Obtain blood and sputum cultures before starting antibiotics to allow later de‑escalation based on susceptibility results 6.

Start oseltamivir or baloxavir as soon as influenza is confirmed; early treatment (within 48 h of symptom onset) maximizes efficacy 8.
Management should follow established influenza treatment guidelines (e.g., CDC/WHO recommendations) irrespective of concurrent COVID‑19 infection 8.

Documented bacterial co‑infection (e.g., Fusobacterium) justifies empirical antibiotic therapy; the general recommendation against routine antibiotics in COVID‑19 does not apply when a bacterial pathogen is identified 6.
Secondary bacterial infections are reported in up to 20 % of patients hospitalized with COVID‑19 and are linked to higher mortality rates 9.

Enforce strict hand hygiene and respiratory precautions for patients with triple infection (SARS‑CoV‑2, influenza, and Fusobacterium) [10][11].
Hand washing with soap and water for 20–40 seconds is recommended 10.
Use alcohol‑based hand sanitizers containing 60–85 % alcohol when soap and water are unavailable 10.
Apply social distancing and mask use to reduce transmission of the respiratory viruses 11.

Review culture results and clinical response within 48–72 hours; de‑escalate or discontinue antibiotics based on susceptibility data to limit antimicrobial resistance [7][6].

All facts are derived from peer‑reviewed sources and reflect current best‑practice recommendations.